Go to
current issue
加入关注
催更
样式： 排序： IF: - GO 导出 标记为已读
-
Joint statement in support of hepatitis C human challenge studies Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-21 Harvey J Alter, Eleanor Barnes, Mia J Biondi, Andrea L Cox, Jake D Eberts, Jordan J Feld, T Jake Liang, Josh Morrison, Charles M Rice, Naglaa H Shoukry, David L Thomas, Jennifer Van Gennip, Charles Weijer
Abstract not available
-
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-18 John V Reynolds, Shaun R Preston, Brian O'Neill, Maeve A Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth O Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B Hanna, Frederick R Bartlett, Alberto Alvarez-Iglesias, Michael P Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Jacintha O'Sullivan
Background The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) with optimum contemporaneous perioperative chemotherapy regimens (epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine [a modified MAGIC regimen]
-
CROSS versus modified MAGIC or FLOT in oesophageal and gastro-oesophageal junction adenocarcinoma Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-18 Peter S N van Rossum, Hanneke W M van Laarhoven
Abstract not available
-
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-09 Giten Khwairakpam, Jessica Hicks, Capucine Pénicaud
Abstract not available
-
Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-09 Raja Atreya, Markus F Neurath
Abstract not available
-
Diagnosis and management of ectopic varices in portal hypertension Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-09 Thomas H Tranah, Jeremy S Nayagam, Stephen Gregory, Sarah Hughes, David Patch, Dhiraj Tripathi, Debbie L Shawcross, Deepak Joshi
Ectopic variceal bleeding is a rare cause of gastrointestinal bleeding that can occur in settings of cirrhotic and non-cirrhotic portal hypertension and is characterised by its development at locations remote from the oesophagus and stomach. Ectopic varices can be difficult to identify and access, and, although a relatively uncommon cause of portal hypertensive bleeding, can represent a difficult diagnostic
-
Serum anti-tissue transglutaminase IgA and prediction of duodenal villous atrophy in adults with suspected coeliac disease without IgA deficiency (Bi.A.CeD): a multicentre, prospective cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-09 Carolina Ciacci, Julio Cesar Bai, Geoffrey Holmes, Abdulbaqi Al-Toma, Federico Biagi, Antonio Carroccio, Rachele Ciccocioppo, Antonio Di Sabatino, Rachel Gingold-Belfer, Mariana Jinga, Govind Makharia, Sonia Niveloni, Gary L Norman, Kamran Rostami, David S Sanders, Edgardo Smecuol, Vincenzo Villanacci, Santiago Vivas, Fabiana Zingone
Background Whether coeliac disease in adults can be diagnosed with serology alone remains controversial. We aimed to evaluate the accuracy of serum anti-tissue transglutaminase IgA (tTG-IgA) in the diagnosis of coeliac disease. Methods In this multicentre, prospective cohort study, adult participants (aged ≥18 years) with suspected coeliac disease without IgA deficiency who were not on a gluten-free
-
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-09 Séverine Vermeire, Silvio Danese, Wen Zhou, Dapo Ilo, Justin Klaff, Gweneth Levy, Xuan Yao, Su Chen, Yuri Sanchez Gonzalez, Xavier Hébuterne, James O Lindsay, Peter D R Higgins, Qian Cao, Hiroshi Nakase, Jean-Frédéric Colombel, Edward V Loftus, Remo Panaccione
Background Upadacitinib is an oral, selective, and reversible JAK inhibitor with demonstrated efficacy in patients with moderately to severely active ulcerative colitis in a phase 2b induction trial, two phase 3 induction trials (U-ACHIEVE Induction and U-ACCOMPLISH), and a primary analysis of the first 451 patients entering a subsequent maintenance trial (U-ACHIEVE Maintenance). Here, we present overall
-
Research in Brief Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-06 Holly Baker
Abstract not available
-
Food as a global health and social priority Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-06
Abstract not available
-
The eosinophil paradox in type 2 high upper gastrointestinal disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-06 Brian Lipworth, Rasads Misirovs, Rory Chan
Abstract not available
-
How can I improve my gut health if I am on a special diet? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-06 Heidi M Staudacher, Caroline J Tuck
Abstract not available
-
The Patient Doctor | Ben Bravery, The Patient Doctor, Hachette Australia (2022), p. 352, £14·99 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-06 Hollie Sherwood-Martin
Abstract not available
-
Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-31 Anna Emilie Kann, Peter Jepsen, Lone Galmstrup Madsen, Joe West, Gro Askgaard
Background Increased knowledge of the causes of death will be essential to prevent premature death in alcohol-related liver disease. We examined cause-specific mortality, including death due to specific cancers, in the 15 years after diagnosis of alcohol-related liver disease. Methods We used nationwide health registries to identify patients (aged ≥18 years) with a first diagnosis of alcohol-related
-
High 10-year mortality in alcohol-related liver disease: where do we go from here? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-31 Jessica L Mellinger
Abstract not available
-
An important step towards the long-term treatment of eosinophilic oesophagitis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-31 Elisa Marabotto, Edoardo Vincenzo Savarino
Abstract not available
-
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-31 Marc E Rothenberg, Evan S Dellon, Margaret H Collins, Ikuo Hirano, Mirna Chehade, Albert J Bredenoord, Alfredo J Lucendo, Jonathan M Spergel, Xian Sun, Jennifer D Hamilton, Eric Mortensen, Elizabeth Laws, Jennifer Maloney, Leda P Mannent, Eilish McCann, Xia Liu, Lila Glotfelty, Arsalan Shabbir
Background Long-term management options that specifically target the underlying inflammation in eosinophilic oesophagitis are needed. Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13; we aimed to assess its long-term efficacy and safety in adults and adolescents with eosinophilic oesophagitis enrolled in part B of the LIBERTY EoE TREET study who continued to part C (part
-
What is the current status of multicancer early detection tests and upper gastrointestinal cancer? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-30 Matt Hoare, Rebecca C Fitzgerald
Abstract not available
-
Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-22 Emmanouil Fokas, Claus Rödel, J Joshua Smith, Julio Garcia-Aguilar, Marc Buyse, Robert Glynne-Jones
Abstract not available
-
NASH drug treatment development: challenges and lessons Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-16 Herbert Tilg, Christopher D Byrne, Giovanni Targher
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy
-
Unsilencing liver disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09
Abstract not available
-
Targeting type 2 immune responses to treat eosinophilic gastritis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Grace L Burns, Simon Keely
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Holly Baker
Abstract not available
-
Britta Siegmund: answering the big questions in IBD Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Tony Kirby
Abstract not available
-
Accessing health care autistically: a routine nasojejunal tube replacement Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Harrie Larrington-Spencer
Abstract not available
-
Poor Little Sick Girls: A Love Letter to Unacceptable Women | Ione Gamble, Poor Little Sick Girls: A Love Letter to Unacceptable Women, Dialogue Books (2023), p. 304, £10·99 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Tanzina Islam
Abstract not available
-
Rare cause of dysphagia in a young woman Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-09 Ahmed Alwali, Maria Witte, Clemens Schafmayer, Imad Kamaleddine
Abstract not available
-
MetALD: new opportunities to understand the role of alcohol in steatotic liver disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-08 Mads Israelsen, Nikolaj Torp, Stine Johansen, Maja Thiele, Aleksander Krag
Abstract not available
-
Gavi's green light for hepatitis B birth dose vaccination in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-08 Paul Adepoju
Abstract not available
-
Surgery in Crohn's disease: patients need MDT-led holistic care Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-08 Kathryn Senior
Abstract not available
-
Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-03 Christy Riggott, Antonina Mikocka-Walus, David J Gracie, Alexander C Ford
Background There is increasing evidence for an influence of the gut–brain axis on the natural history of inflammatory bowel disease (IBD). Psychological therapies could, therefore, have beneficial effects in individuals with IBD, but data are conflicting. We aimed to update our previous systematic review and meta-analysis to assess whether the inclusion of more randomised controlled trials (RCTs) showed
-
Psychological therapies in inflammatory bowel disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-03 Andrea Shin
Abstract not available
-
Ensuring patients with malignant bowel obstruction are central in research and clinical decisions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-01 Jason W Boland, Elaine G Boland
Abstract not available
-
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-08-01 Robert S Krouse, Garnet L Anderson, Kathryn B Arnold, Cynthia A Thomson, Valentine N Nfonsam, Mazin F Al-Kasspooles, Joan L Walker, Virginia Sun, Angeles Alvarez Secord, Ernest S Han, Alberto M Leon-Takahashi, David Isla-Ortiz, Phillip Rodgers, Samantha Hendren, Marco Sanchez Salcedo, Jonathan A Laryea, Whitney S Graybill, Devin C Flaherty, Harveshp Mogal, Thomas J Miner, Jeremiah L Deneve
Background Malignant small bowel obstruction has a poor prognosis and is associated with multiple related symptoms. The optimal treatment approach is often unclear. We aimed to compare surgical versus non-surgical management with the aim to determine the optimal approach for managing malignant bowel obstruction. Methods S1316 was a pragmatic comparative effectiveness trial done within the National
-
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-27
Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger
-
Poor disease knowledge among people living with hepatitis B in The Gambia and Tanzania Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-27 Erwan Vo-Quang, Rohey Bangura, Naveeda Adam, Gibril Ndow, Yusuke Shimakawa, Maud Lemoine
Abstract not available
-
A global investment case for hepatitis B elimination: a modelling study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-27 Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott
Hepatitis B is estimated to cause 500 000–900 000 deaths globally each year. WHO has targets for elimination by 2030; however, progress has stalled due to multiple barriers, notably a paucity of global funding and insufficient evidence on the economic burden of disease. Using a dynamic mathematical model of hepatitis B transmission, disease progression, and mortality in the six WHO regions, we estimate
-
Is it time for a paradigm shift in treatment guidelines for chronic hepatitis B? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-27 Asgeir Johannessen
Abstract not available
-
WHO 2030 HBV elimination goals: a goal too far? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-27 Seng Gee Lim
Abstract not available
-
Time to scale up testing and treatment for HBV and HCV in the WHO Eastern Mediterranean Region Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-26 Ahmed Sabry Alaama, Capucine Pénicaud, Oriel Fernandes, Muhammad S Jamil, Joumana Hermez, Yvan J-F Hutin
Abstract not available
-
Clinical application of circulating tumour DNA in colorectal cancer Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-24 Matthew Loft, Yat Hang To, Peter Gibbs, Jeanne Tie
Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to revolutionise the personalised management of colorectal cancer. For patients with early-stage disease, emerging clinical applications include the assessment of molecular residual disease after surgery, the monitoring of adjuvant chemotherapy efficacy, and early detection of recurrence during surveillance. In the advanced
-
Blood-based colorectal cancer screening: are we ready for the next frontier? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-21 Christina P Wang, Sarah J Miller, Aasma Shaukat, Lina H Jandorf, David A Greenwald, Steven H Itzkowitz
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2023; published online July 4. https://doi.org/10.1016/S2468-1253(23)00157-7 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-18
Abstract not available
-
Spleen stiffness to identify clinically significant portal hypertension Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-18 Cristina Ripoll, Alexander Zipprich
Abstract not available
-
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-18 Elton Dajti, Federico Ravaioli, Romanas Zykus, Pierre-Emmanuel Rautou, Laure Elkrief, Ivica Grgurevic, Horia Stefanescu, Masashi Hirooka, Mirella Fraquelli, Matteo Rosselli, Pik Eu Jason Chang, Fabio Piscaglia, Thomas Reiberger, Elba Llop, Sebastian Mueller, Giovanni Marasco, Annalisa Berzigotti, Agostino Colli, Davide Festi, Antonio Colecchia, Dante Romagnoli
Background The diagnosis of clinically significant portal hypertension is crucial for prognosis and treatment guidance in patients with compensated advanced chronic liver disease (ACLD). Spleen stiffness measurement (SSM) might improve the non-invasive diagnosis of clinically significant portal hypertension, but previous studies have reported heterogeneous SSM cutoffs. We aimed to evaluate the accuracy
-
Semaglutide in NASH-related cirrhosis: still a long way to go? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-12
Abstract not available
-
Semaglutide in NASH-related cirrhosis: still a long way to go? – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-12
Abstract not available
-
-
-
An Indigenous First Nations perspective on liver health Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-12
Abstract not available
-
SH!T BAG: a young adult novel about dealing with bowel disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-12
Abstract not available
-
More is not always better for novel hepatitis B therapies Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-10 Sabela Lens, Xavier Forns
Abstract not available
-
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-10 Man-Fung Yuen, Tarik Asselah, Ira M Jacobson, Maurizia Rossana Brunetto, Harry L A Janssen, Tetsuo Takehara, Jin Lin Hou, Thomas N Kakuda, Tom Lambrecht, Maria Beumont, Ronald Kalmeijer, Carine Guinard-Azadian, Cristiana Mayer, John Jezorwski, Thierry Verbinnen, Oliver Lenz, Umesh Shukla, Michael Biermer
Background JNJ-73763989 (JNJ-3989), a small interfering RNA, targets all hepatitis B virus (HBV) RNAs, reducing all HBV proteins. JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV replication. We aimed to evaluate the efficacy (ie, antiviral activity) and safety of these therapeutics in combination with nucleos(t)ide analogues in patients with chronic hepatitis
-
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-06 Tommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, Axel Dignass, Iris Dotan, Fernando Magro, Anne M Griffiths, Vipul Jairath, Marietta Iacucci, Gerassimos J Mantzaris, Colm O'Morain, Walter Reinisch, David B Sachar, Dan Turner, Takayuki Yamamoto, David T Rubin, Laurent Peyrin-Biroulet, Subrata Ghosh, Silvio Danese
Many patients with inflammatory bowel disease (IBD) have persistent symptoms and disease activity despite the best available medical or surgical treatments. These patients are commonly referred to as having difficult-to-treat IBD and need additional therapeutic strategies. However, the absence of standard definitions has impeded clinical research efforts and comparisons of data. Under the guidance
-
NAFLD and liver-related events: does type 2 diabetes have a key role? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-04 Eduardo Vilar-Gomez
Abstract not available
-
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-07-04 Daniel Q Huang, Nabil Noureddin, Veeral Ajmera, Maral Amangurbanova, Ricki Bettencourt, Emily Truong, Tolga Gidener, Harris Siddiqi, Abdul M Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Masato Yoneda, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem Kuru Oz, Ayse Erden, Alina M Allen, Mazen Noureddin, Rohit Loomba
Background Data are scarce regarding the development of hepatic decompensation in patients with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes. We aimed to assess the risk of hepatic decompensation in people with NAFLD with and without type 2 diabetes. Methods We did a meta-analysis of individual participant-level data from six cohorts in the USA, Japan, and Turkey. Included
-
Homecare medicines services are failing patients in the UK Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-06-29
Abstract not available
-
Assessment of hepatocellular carcinoma surveillance practices in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-06-26 Manaswita Tappata, Marina Farah, Chimaobi Anugwom, Amir S Seid, Ijeoma Ifeorah, Jose D Debes
Abstract not available
-
Fibroblasts in liver cancer: functions and therapeutic translation Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-06-26 Silvia Affo, Aveline Filliol, Gregory J Gores, Robert F Schwabe
Accumulation of fibroblasts in the premalignant or malignant liver is a characteristic feature of liver cancer, but has not been therapeutically leveraged despite evidence for pathophysiologically relevant roles in tumour growth. Hepatocellular carcinoma is a largely non-desmoplastic tumour, in which fibroblasts accumulate predominantly in the pre-neoplastic fibrotic liver and regulate the risk for
-
Launch of the International Living Donor Liver Transplantation Outcomes Registry Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-06-22 Sebastian Staubli, Alexander Steen Grover, Benedict R H Turner, Dimitri A Raptis, Michael Spiro, Pascale Tinguely, Marina Berenguer, Mohamed Rela
Abstract not available
更新日期：2023-09-08
京公网安备 11010802027423号